Goserelin
As of the edition of 20 October 2026, Goserelin is a protein: marketed, first approved in 1987 (FR); acts on GNRHR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1994
- Kind
- Protein
- Brand name
- Zoladex
- First approved
- 26 January 1987 (FR)
- Approvals on record
- 10 in 6 regions
- Holder of the most recent approval
- TerSera Therapeutics; 2 holders in all
- Registered trials
- 221, 31 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Skin and connective tissue; Pregnancy and women's health; Hormones; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Goserelin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | P30968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 21 | 8 | 6 | 2 |
| Phase 1 | 17 | 10 | 3 | 3 |
| Phase 2 | 106 | 47 | 28 | 16 |
| Phase 3 | 65 | 33 | 17 | 7 |
| Phase 4 | 12 | 2 | 3 | 3 |
| All trials | 221 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Earlier holder | 1989 to now |
| TerSera Therapeutics | Acquired holder and Lead sponsor of trials | 2017 to now |